| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1016/J.AMJMED.2005.12.011 |
| P698 | PubMed publication ID | 16483863 |
| P2093 | author name string | David R Staskin | |
| Scott A MacDiarmid | |||
| P433 | issue | 3 Suppl 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 9-15 | |
| P577 | publication date | 2006-03-01 | |
| P1433 | published in | American Journal of Medicine | Q2842959 |
| P1476 | title | Using anticholinergics to treat overactive bladder: the issue of treatment tolerability | |
| P478 | volume | 119 |
| Q89464176 | Acyloxyacyl hydrolase modulates voiding activity |
| Q36386201 | Adherence to Oral Therapy for Urgency Urinary Incontinence: Results from the Anticholinergic Versus Botox Comparison (ABC) Trial |
| Q37879017 | Antimuscarinic drugs: review of the cognitive impact when used to treat overactive bladder in elderly patients. |
| Q33696642 | Cost-effectiveness of mirabegron compared to tolterodine ER 4 mg for overactive bladder in Canada |
| Q37283717 | Development of oxybutynin chloride topical gel for overactive bladder |
| Q33692394 | Dose escalation improves therapeutic outcome: post hoc analysis of data from a 12-week, multicentre, double-blind, parallel-group trial of trospium chloride in patients with urinary urge incontinence |
| Q34009583 | Drug-induced hyperhidrosis and hypohidrosis: incidence, prevention and management |
| Q44777025 | Efficacy and safety of once-daily oxybutynin patch versus placebo and propiverine in Japanese patients with overactive bladder: A randomized double-blind trial |
| Q37672836 | Efficacy and safety of solifenacin succinate 10 mg once Daily: A multicenter, phase III, randomized, double-blind, placebo-controlled, parallel-group trial in patients with overactive bladder |
| Q48266047 | Inhibition of salivary secretion by tolterodine transdermal patch |
| Q64085603 | Long-Term Efficacy of Mirabegron Add-On Therapy to Antimuscarinic Agents in Patients With Spinal Cord Injury |
| Q34540490 | Lower urinary tract symptoms increase the risk of falls in older men |
| Q84757653 | Management of urinary incontinence |
| Q35057494 | Mechanisms of disease: involvement of the urothelium in bladder dysfunction |
| Q34625687 | Mirabegron: a safety review |
| Q51166031 | Optimum Dose of Once-Daily Oxybutynin Patch in Japanese Patients with Overactive Bladder: A Randomized Double-Blind Trial Versus Placebo. |
| Q37283566 | Oxybutynin topical gel in the treatment of overactive bladder |
| Q83811785 | Patient-reported most bothersome symptoms in OAB: post hoc analysis of data from a large, open-label trial of solifenacin |
| Q37017434 | Pharmacologic management of overactive bladder |
| Q37399563 | Rationale for the use of anticholinergic agents in overactive bladder with regard to central nervous system and cardiovascular system side effects. |
| Q42679416 | Solifenacin and tolterodine are equally effective in the treatment of overactive bladder symptoms |
| Q36655193 | Solifenacin provides effective antimuscarinic therapy for the complete management of overactive bladder |
| Q38081463 | Systematic review of the relationship between bladder and bowel function: implications for patient management |
| Q37018934 | Treatment of overactive bladder in the aging population: focus on darifenacin |
| Q43835601 | Triple therapy in refractory detrusor overactivity: a preliminary study |
Search more.